KPTI - KPTI Has sNDAs In Process That Could More Than Double Its Share Price If Approved
Karyopharm Therapeutics Inc. (KPTI) is a commercial pharmaceutical company focused on drugs/therapies directed against nuclear transport and related targets for the treatment of cancer and other major diseases. KPTI employs approximately 350 people out of their Newton, MA headquarters. The company's lead product, Xpovio (aka Selinexor), was first approved by the FDA last July 2019 as a 4th line therapy to treat Multiple Myeloma ("MM") and commercially launched shortly thereafter. Xpovio was prescribed ~1,400 times in 2H2019 & 860 times in Q1 2020 by ~700 physicians. Xpovio's list price is ~$22,000 and, per KPTI, gross